Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.79 - $12.36
Previous CloseN/A
Volume5.68M
Average Volume (3M)17.24M
Market Cap
$2.07B
Enterprise Value$1.67B
Total Cash (Recent Filing)$528.22M
Total Debt (Recent Filing)$88.08M
Price to Earnings (P/E)―
Beta3.24
Next Earnings
Nov 05, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding427,312,960
10 Day Avg. Volume16,239,426
30 Day Avg. Volume17,242,798
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue25.94
Enterprise Value/Gross Profit-690.22
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$5.95Price Target Upside22.93% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Operational EfficiencyRecent cost-cutting measures are expected to lower operational expenses by approximately 35%, which is likely to improve financial efficiency.
Revenue GenerationThe company's steady influx of revenues from partners is encouraging.
Strategic PartnershipsFrom a partnering perspective, Recursion is opting for quality over quantity, focusing on large potentially transformational collaborations with significant financial benefits.
Bears Say
Adverse EventsApproximately 80% of patients in the ongoing study experienced at least one treatment-related adverse event.
Asset DiscontinuationRXRX announced discontinuation of its most advanced pipeline assets.
Price Target ReductionAnalyst reduced the price target from $4 to $3 and reiterated a market perform rating.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $3.79 and its highest was $12.36 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.07B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 48 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.353 by -$0.057.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 427,312,960 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.353. Following the earnings report the stock price went down -4.655%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.95 (22.93% Upside)
$5.95 (22.93% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $223.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.21%
12-Months-Change
Fundamentals
Return on Equity
-86.34%
Trailing 12-Months
Asset Growth
67.86%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in technology and partnerships, showcasing Recursion's innovative approach and strong cash management. However, there are concerns regarding long drug development timelines, regulatory uncertainties, and reliance on partnerships for revenue.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$5.95
▲(22.93% Upside)
Technical Analysis
Agios Pharma
―
Galapagos
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
3.60% Insiders
11.94% Mutual Funds
39.96% Other Institutional Investors
21.76% Public Companies and Individual Investors